MedTrace Logo

hepatomiR cACLD Study

NCT06432582 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 156

Last updated 2025-09-09

No results posted yet for this study

Summary

This study looks to gather data on hepatomiR, a CE-certified test already intended for gauging liver-related outcomes, in order to define a cut-off regarding specific decompensation events (ascites, variceal hemorrhage, hepatic encephalopathy) in chronic liver disease (CLD). Based on these data, it is aimed to advance the current understanding of factors driving decompensation, with potential repercussions for future risk management and therapy.

Conditions

Interventions

DIAGNOSTIC_TEST

hepatomiR

hepatomiR is a CE-certified test intended for gauging liver-related outcomes. It quantifies the levels of hsa-miR-122-5p, hsa-miR-192-5p, and hsa-miR-151a-5p in human plasma samples. A proprietary algorithm is then used to compute a liver function score (hepatomiR p-score).

Sponsors & Collaborators

  • University Hospital St. Polten

    collaborator OTHER

  • Karl Landsteiner University of Health Sciences

    lead OTHER

Principal Investigators

  • Andreas Maieron, PD Dr. · Karl Landsteiner University of Health Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-15
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06432582 on ClinicalTrials.gov